Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
0.6349
+0.0732 (13.03%)
At close: Nov 21, 2025, 4:00 PM EST
0.6174
-0.0175 (-2.76%)
After-hours: Nov 21, 2025, 7:56 PM EST
Harvard Bioscience Market Cap
Harvard Bioscience has a market cap or net worth of $28.3 million as of November 21, 2025. Its market cap has decreased by -76.99% in one year.
Market Cap
28.30M
Enterprise Value
64.20M
1-Year Change
-76.99%
Ranking
Category
Stock Price
$0.63
Market Cap Chart
Since March 19, 2001, Harvard Bioscience's market cap has decreased from $173.50M to $28.30M, a decrease of -83.69%. That is a compound annual growth rate of -7.08%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 21, 2025 | 28.30M | -69.24% |
| Dec 31, 2024 | 92.00M | -59.72% |
| Dec 29, 2023 | 228.40M | 97.92% |
| Dec 30, 2022 | 115.40M | -59.89% |
| Dec 31, 2021 | 287.70M | 72.07% |
| Dec 31, 2020 | 167.20M | 44.01% |
| Dec 31, 2019 | 116.10M | -2.11% |
| Dec 31, 2018 | 118.60M | 3.04% |
| Dec 29, 2017 | 115.10M | 9.83% |
| Dec 30, 2016 | 104.80M | -11.04% |
| Dec 31, 2015 | 117.80M | -35.91% |
| Dec 31, 2014 | 183.80M | 26.15% |
| Dec 31, 2013 | 145.70M | 15.45% |
| Dec 31, 2012 | 126.20M | 14.42% |
| Dec 30, 2011 | 110.30M | -4.42% |
| Dec 31, 2010 | 115.40M | 9.70% |
| Dec 31, 2009 | 105.20M | 29.08% |
| Dec 31, 2008 | 81.50M | -42.24% |
| Dec 31, 2007 | 141.10M | -9.96% |
| Dec 29, 2006 | 156.70M | 15.56% |
| Dec 30, 2005 | 135.60M | -3.49% |
| Dec 31, 2004 | 140.50M | -47.56% |
| Dec 31, 2003 | 267.90M | 170.88% |
| Dec 31, 2002 | 98.90M | -62.67% |
| Dec 31, 2001 | 264.90M | 52.68% |
View and export this data all the way back to 2001. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 939.79B |
| Johnson & Johnson | 487.91B |
| AbbVie | 411.64B |
| UnitedHealth Group | 279.99B |
| AstraZeneca | 275.69B |
| Novartis AG | 244.75B |
| Merck & Co. | 235.92B |
| Abbott Laboratories | 219.36B |